NCT05201898

Brief Summary

Incidence of cardiometabolic disease (CMD) continues to rise, which consumes huge medical resources in Taiwan. The effectiveness of dietary therapy for CMD has not been locally evaluated in detail. CVD is an important risk factor for dementia. At the present time, there is no effective treatment available for dementia. Early prevention is extremely important. Our previous studies have shown that Taiwanese dementia protective diet is very similar to cardiovascular prevention and control diet, meaning that effective dietary therapy may not only control CVD but also prevent dementia development. Therefore, this study intends to document the effects of dietary intervention on cardiovascular disease risk factor control, the long-term outcomes on the occurrence of cardiovascular events, and the maintenance of cognitive function for patients with coronary artery disease.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable cardiovascular-diseases

Timeline
Completed

Started Dec 2021

Shorter than P25 for not_applicable cardiovascular-diseases

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2021

Completed
4 days until next milestone

Study Start

First participant enrolled

December 23, 2021

Completed
29 days until next milestone

First Posted

Study publicly available on registry

January 21, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 14, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 14, 2023

Completed
Last Updated

October 27, 2023

Status Verified

October 1, 2023

Enrollment Period

1.1 years

First QC Date

December 19, 2021

Last Update Submit

October 25, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change from baseline in diet quality at Year 1, 2, and 3.

    Diet quality is estimated according to the daily intake of nutrients and the distribution of the six food groups, with a qualified food frequency questionnaire. The six food groups include: 1. Whole grains and starchy vegetables 2. Protein foods: soybeans, fish, eggs, and meat 3. Vegetables 4. Fruits 5. Dairy 6. Oils, nuts \& seeds

    Baseline, year 1, 2 and 3

  • Change from baseline in concentrations of cardiovascular risk factors at Month 6, 12, 18, 24,30, and 36.

    Cardiovascular risk factors include total cholesterol,triglyceride, low-density lipoprotein ,high-density lipoprotein, uric acid, glucose, HbA1C.

    Baseline and Month 6, 12, 18, 24, 30, and 36.

  • Events of cardiovascular diseases at Year 6.

    CVD or non-CVD death, stroke, acute myocardial infarction, hospitalization for acute coronary syndrome, hospitalization for coronary intervention surgery, hospitalization for various cardiovascular diseases, hospitalization for heart failure, hospitalization for other CVD diseases, new-onset heart arrhythmia, new-onset peripheral blood vessels block

    Year 6.

Secondary Outcomes (6)

  • Change from baseline in the dosage of prescribed drugs at Month 6, 12, 18, 24,30, and 36.

    Baseline and Month 6, 12, 18, 24, 30, and 36.

  • Change from baseline in cardiovascular risk score

    Baseline, year 1, 2 and 3.

  • Change from baseline in concentrations of inflammatory markers at Year 1, 2, and 3.

    Baseline, year 1, 2 and 3.

  • Change from baseline in scores of Montreal Cognitive Assessment at Year 1, 2, and 3.

    Baseline, year 1, 2 and 3.

  • Change from baseline in scores of Number Cancellation test

    Baseline, year 1, 2 and 3.

  • +1 more secondary outcomes

Study Arms (3)

usual medical management

PLACEBO COMPARATOR

with regular doctor visits every 3 months

Other: control:usual medical management

usual medical management+individual dietary consultation

EXPERIMENTAL

with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit

Other: control:usual medical managementBehavioral: intervention 1:usual medical management+individual dieting consultation

usual medical management+individual dietary consultation+ daily tea drinking

EXPERIMENTAL

with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking

Other: control:usual medical managementBehavioral: intervention 1:usual medical management+individual dieting consultationBehavioral: intervention 2:usual medical management+individual dieting consultation+ daily tea drinking

Interventions

with regular doctor visits every 3 months

usual medical managementusual medical management+individual dietary consultationusual medical management+individual dietary consultation+ daily tea drinking

with regular doctor visits every 3 months and dietitian visits every 3 months

usual medical management+individual dietary consultationusual medical management+individual dietary consultation+ daily tea drinking

with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking

usual medical management+individual dietary consultation+ daily tea drinking

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have received percutaneous transluminal coronary artery surgery.
  • Stable drug control for more than one month

You may not qualify if:

  • Suffer from cancer and undergo chemotherapy or surgery within one year.
  • Those who have a major illness in hospital within one year.
  • Those with kidney disease stage 5 (inclusive) or above
  • Those whose life expectancy does not exceed half a year
  • Patients with diagnosed dementia
  • Those who do not want to be tracked

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taipei Veterans General Hospital

Taipei, Beitou District, 112, Taiwan

Location

MeSH Terms

Conditions

Cardiovascular Diseases

Study Officials

  • Wen-Harn Pan, Ph.D

    Institute of Biomedical Sciences, Academia Sinica

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Distinguished Research Fellow, Principal Investigator

Study Record Dates

First Submitted

December 19, 2021

First Posted

January 21, 2022

Study Start

December 23, 2021

Primary Completion

February 14, 2023

Study Completion

February 14, 2023

Last Updated

October 27, 2023

Record last verified: 2023-10

Locations